$214 Million is the total value of Prosight Management, LP's 44 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMY | Exit | BRISTOL MYERS SQUIBB CO | $0 | – | -8,100 | -100.0% | -0.23% | – |
| Exit | AXSOME THERAPEUTICS INCput | $0 | – | -6,000 | -100.0% | -0.27% | – | |
| TLGT | Exit | TELIGENT INC NEW | $0 | – | -1,484,527 | -100.0% | -0.28% | – |
| TNET | Exit | TRINET GROUP INC | $0 | – | -28,104 | -100.0% | -0.70% | – |
| PRTK | Exit | PARATEK PHARMACEUTICALS INC | $0 | – | -450,000 | -100.0% | -0.80% | – |
| Exit | ALLAKOS INCput | $0 | – | -20,700 | -100.0% | -0.87% | – | |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -160,883 | -100.0% | -0.99% | – |
| EVH | Exit | EVOLENT HEALTH INCcl a | $0 | – | -279,390 | -100.0% | -1.11% | – |
| RCM | Exit | R1 RCM INC | $0 | – | -200,000 | -100.0% | -1.14% | – |
| SBBP | Exit | STRONGBRIDGE BIOPHARMA PLC | $0 | – | -1,258,224 | -100.0% | -1.16% | – |
| Exit | ARENA PHARMACEUTICALS INCcall | $0 | – | -142,400 | -100.0% | -2.84% | – | |
| ARQL | Exit | ARQULE INC | $0 | – | -450,326 | -100.0% | -3.95% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.